Analyzing Icon (NASDAQ:ICLR) & Stevanato Group (NYSE:STVN)

Icon (NASDAQ:ICLR – Get Free Report) and Stevanato Group (NYSE:STVN – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Icon and Stevanato Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Icon 5.45% 7.73% 4.39%
Stevanato Group 11.24% 10.51% 6.22%

Insider & Institutional Ownership

95.6% of Icon shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Icon has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Earnings and Valuation

This table compares Icon and Stevanato Group”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Icon $8.23 billion 1.81 $229.34 million $5.81 33.59
Stevanato Group $1.34 billion 3.47 $158.21 million €0.58 26.51

Icon has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Icon and Stevanato Group, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Icon 1 9 9 1 2.50
Stevanato Group 0 5 2 2 2.67

Icon currently has a consensus target price of $213.76, indicating a potential upside of 9.53%. Given Icon’s higher possible upside, research analysts plainly believe Icon is more favorable than Stevanato Group.

Summary

Icon beats Stevanato Group on 9 of the 15 factors compared between the two stocks.

About Icon

(Get Free Report)

ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.

About Stevanato Group

(Get Free Report)

Stevanato Group is an Italian provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and diagnostic industries. Founded in 1949 by Giovanni Stevanato, the company began as a glassmaking business and has expanded into a global supplier of products and services for the life sciences sector. The company makes primary packaging for injectable medicines, including glass vials, cartridges, syringes and ampoules. Its offerings also include ready-to-use containers, as well as services such as product development, analytical testing and packaging support.

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.